CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
Digoxin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01436201
NCT01436201Phase 1Completed

Effect of Dulaglutide (LY2189265) on the Pharmacokinetics of Digoxin in Healthy Subjects

Eli Lilly and Company·interventional·Posted Sep 19, 2011·Updated Oct 7, 2014

In Brief

A Phase 1 clinical trial evaluating Digoxin and Dulaglutide for Diabetes Mellitus, Type 2. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this study is to study how the body processes digoxin and the effect of dulaglutide on how digoxin is processed by the body. Information about any side effects that may occur will also be collected. This study is for research purposes only and is not intended to treat any medical condition. This research study requires that a blood sample be obtained and stored for future research involving genetic analysis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 19, 2011
Enrollment StartSep 1, 2011
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.8 years ago

Interventions

Digoxindrug

Administered orally

Dulaglutidebiological

Administered as subcutaneous injection